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Copy-number variations cause genomic disorders. Triplications, unlike deletions and duplications, are poorly understood because of
challenges in molecular identification, the choice of a proper model system for study, and awareness of their phenotypic consequences.
We investigated the genomic disorder Charcot-Marie-Tooth disease type 1A (CMT1A), a dominant peripheral neuropathy caused by a
1.4 Mb recurrent duplication occurring by nonallelic homologous recombination. We identified CMT1A triplications in families in
which the duplication segregates. The triplications arose de novo from maternally transmitted duplications and caused a more severe
distal symmetric polyneuropathy phenotype. The recombination that generated the triplication occurred between sister chromatids
on the duplication-bearing chromosome and could accompany gene conversions with the homologous chromosome. Diagnostic testing
for CMT1A (n ¼ 20,661 individuals) identified 13% (n ¼ 2,752 individuals) with duplication and 0.024% (n ¼ 5 individuals) with
segmental tetrasomy, suggesting that triplications emerge from duplications at a rate as high as ~1:550, which is more frequent than
the rate of de novo duplication. We propose that individuals with duplications are predisposed to acquiring triplications and that the
population prevalence of triplication is underascertained.Genomic duplication was first visualized in the 1930s
when Calvin Bridges used polytene chromosomes to
show that a phenotype consisting of a reduction in the
size of the eye in Drosophila melanogaster was due to a
duplication of the Bar locus at cytological band X16A;
the phenotype reverted to wild-type with loss of the
duplication.1 Bar duplication and its reversion were hy-
pothesized to occur by unequal crossing-over.2–4 Recent
evidence has suggested BarH1 as the dosage-sensitive
gene associated with the Bar phenotype.5 Bridges also
noted that Ultra-Bar, a mutant isolated from the Bar stock
and with a more severe phenotype (an even further slit
eye), was associated with an apparent triplication at the
locus.1 Questions were raised as to the frequency, molecu-
lar origin, and precise mechanism for triplication. How-
ever, efforts to reach conclusions experimentally were
hampered by technological challenges and limitations in
the knowledge of genomics and the mechanisms for
genomic rearrangements.
After three quarters of a century, another chance to illu-
minate some of the questions raised by the observations of
Bridges has been offered, although by work from a
completely differentmodel organism,Homo sapiens. Dupli-
cation at the human chromosomal region 17p12 causes
Charcot-Marie-Tooth disease type 1A (CMT1A [MIM
118220]), the most common form of CMT1, but to date,
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characterized by distal muscle weakness and atrophy
and reduced nerve conduction velocities (NCVs) of both
motor and sensory nerves, it manifests clinically as a
distal symmetric polyneuropathy (DSP).6 The disease is
clinically heterogeneous with age-dependent penetrance.
Abnormal NCV (conduction velocity of the motor median
nerve < 38 m/s) is highly diagnostic of CMT1 and is a fully
penetrant trait independent of age.7 The molecular mech-
anism for CMT1A has been extensively studied in affected
individuals throughout the world, and the 1.4 Mb recur-
rent duplication has been shown to result from nonallelic
homologous recombination (NAHR) between directly ori-
ented ectopic substrate copies of flanking low-copy repeats
(LCRs).8,9 This NAHR event is influenced by alleles of
PRDM9 (MIM 609760), which encodes a protein important
for homologous recombination.10 NAHR can occur either
via interchromosomal crossover, i.e., NAHR between ho-
mologous chromosomes, or via intrachromosomal cross-
over, i.e., NAHR between sister chromatids. Theoretically,
if NAHR occurs on chromosomes with preexisting duplica-
tions, recurrent tandem triplications can be produced.
To date, interstitial triplications have been observed in
association with different human diseases, including
genomic disorders (such as the 22q11.2 triplication) and
common complex traits (such as Parkinson disease and he-
reditary pancreatitis).11–20 They often impart a more severeouston, TX 77030, USA; 2State Key Laboratory of Genetic Engineering and
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Figure 1. Clinical Phenotypes and Copy-Number Analyses in Family 1
On the left, pictures illustrate mild muscle atrophy of the mother (top left) and severe muscle atrophy of the lower leg and handmuscles
and severe pes cavus deformity (extremely high-arched foot) in the index individual (bottom left), clinically indicatingmore severe DSP.
NCVs of themedianmotor nerve for themother and index individual are listed in the pedigree. On the right, array CGH and FISH results
show duplication of the CMT1A-associated region in themother (first panel) and sibling (third panel), neutral copy number in the father
(second panel), and triplication in the index individual (fourth panel). In the FISH experiments, the target and control probes used were
P150M12 and RP1-178F10, respectively.phenotype than do duplications because of further incre-
ments in gene dosage. Individuals who have segmental tet-
rasomy of the CMT1A-associated region as a result of ho-
mozygous duplication have been shown to exhibit severe
neurological phenotypes.8,21 Evidence from a rat model
for CMT1A has also suggested that an increase in copy
number of the transgene PMP22 (MIM 601097) results in
a more severe phenotype.22 However, it is not known
whether CMT1A triplications could similarly convey a
strong dosage effect, whether gene dosage effects in trans
(i.e., homozygous duplication) versus cis (i.e., triplication)
behave differently perhaps as a result of position effects,
whether triplications arise de novo via a double crossover
or arise from a pre-existing duplication, and what the prev-
alence of triplication is.
We identified and systematically studied families in
which dominant CMT segregates and in which affected
members from subsequent generations present with a
more severe clinical neuropathy phenotype than do sib-
lings or parents (an observation somewhat reminiscent
of the genetic phenomenon of anticipation). All studies
were approved by the institutional review boards of their
respective institutions: Baylor College of Medicine, Tel
Aviv Medical Center, and Vanderbilt University. Detailed
clinical descriptions and nerve-conduction-study values
can be found in the Supplemental Data, available online.
CMT can have a widely varying severity of the clinical
phenotype, and this variation can occur within the same
family affected by the CMT1A duplication21 and even inThe Ameidentical twins.23 We identified two families in which
one member appears to have disease at the extreme end
of severity and out of proportion with the usual clinical
variation seen within a family in which the CMT1A
duplication segregates. These outlier individuals at the
phenotypic extreme showed more severe DSP upon both
clinical examination and objective electrophysiological
measurements (Figures 1 and 2 and Table S1). Remarkably,
the fact that these outlier individuals have phenotypes
more severe than those of older family members suggests
the possibility of a different underlying pathological
mechanism.
We hypothesized that the degree of severity of the
clinical phenotype is associated with the copy number of
the chromosomal region. To test this hypothesis, we
performed locus-specific high-density array comparative
genomic hybridization (CGH) and interphase fluorescence
in situ hybridization (FISH). We used an Agilent 8X60k
aCGH design with median probe spacing at ~300 bp to
interrogate the human 17p12 region. Array CGH detected
copy number of the 1.4MbCMT1A-associated genomic in-
terval of two, three, or four (Figures 1 and 2). Themolecular
copy-number gain correlated with the severity of clinical
phenotype (Figures 1 and 2). FISH data suggested that
the new rearrangement occurred on the chromosome
with existing duplication, given the 3:1 ratio of experi-
mental (red) fluorescence signals to control (green) signals
on the rearranged chromosome (Figure 1, ‘‘trip 17’’) versus
the 1:1 ratio on the normal chromosome (Figure 1, ‘‘nl 17’’)rican Journal of Human Genetics 94, 462–469, March 6, 2014 463
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Figure 2. NCVs and Copy-Number Analyses in Family 2
Array-CGH analysis revealed that the index individual carries four
copies, the mother and grandmother carry three copies, and the
other family members carry two copies of the CMT1A-associated
region. NCVs were lower in individuals with abnormal copy num-
ber than in healthy individuals. A very low NCV was observed in
the index individual. The following abbreviation is used: NA, not
assayed.and the 2:1 ratio on both homologous chromosomes with
homozygous duplication (Figure 7d in Lupski et al.8).
To investigate the mechanism of the crossovers, we de-
signed microsatellite genotyping assays to phase haplo-
types of the duplicated regions and flanking regions. We
chose eight markers from the literature and seven newly
developed markers with a preference for a high degree of
heterozygosity and long repeat units (penta-, tetra-, or tri-
nucleotides) (Figure 3A and Table S2).24,25 Taking into
account the prior knowledge of array-CGH-ascertained
copy number for eachmarker, analysis of themicrosatellite
genotyping data yielded size and copy-number informa-
tion of the alleles at each locus. Haplotypes were
constructed on the basis of the most parsimonious expla-
nation of segregation and minimum number of recombi-
nation events required. In both families, the de novo
triplication event arose from a pre-existing duplication
and occurred during maternal meiosis (Figures 3B and
3C). This further confirmed that the segmental tetrasomy
was a result of triplication instead of homozygous duplica-
tion. The duplications in both mothers were inferred to be
products of interchromosomal NAHR in a previous gener-
ation because the duplicated alleles in cis were of differing
sizes for most loci examined. In family 2, the triplication
arose via intrachromosomal NAHR (Figure 3C). In the
maternal meiosis that led to the index individual in
family 1, crossover activity appeared to be more compli-
cated. In addition to one NAHR crossover that created
the triplication, a second gene-conversion event most464 The American Journal of Human Genetics 94, 462–469, March 6likely exchanged alleles between the maternal homolo-
gous chromosomes (Figures 3B and 3D). Accompanying
the transmission of duplication across generations in
meiosis, crossing-over with the homologous chromosome
was observed in regions distal to the duplication. This was
evident in a comparison of the phased chromosomes be-
tween the mother (3329) and uncle in family 1, as well
as those of the mother (KSLIII2), uncle (KSLIII1), and
grandmother (KSLII1) in family 2.
Although CMT1A duplications usually arise from inter-
chromosomal NAHR (Figure 4A), estimated to be at least
50-fold greater than intrachromosomal NAHR,26 we pro-
pose that triplications can arise from duplications through
interchromosomal (Figure 4B) or intrachromosomal (Fig-
ures 4D–4F) NAHR. The rearrangements in family 2 can be
explained by intrachromosomal NAHR between flanking
LCRs or the duplicated segments (Figures 4D–4F). The trip-
lication in family1was alsoproducedby intrachromosomal
NAHR. However, a gene conversion potentially exchanged
part of the triplicated CMT1A-associated segment for the
chromosome in trans. The combination of intrachromo-
somal NAHR and interchromosomal allelic recombination
brings about a variety of possible mechanisms, four of
which are shown in Figures 4G–4J. These two events can
occur concurrently or in two separate cell divisions.
The unexpected allelic crossovers and/or gene conver-
sions accompanying transmissions of duplications or the
de novo duplication-to-triplication process observed in
the two families can be potentially explained by the asym-
metry between homologous chromosomes posed by the
duplication and the resulting increased probability of
ectopic synapsis27 facilitating subsequent recombination.
This hypothesis is supported by the ‘‘oblique synapsis’’ in
Bar chromosomes, as noted by Bridges, and is further rein-
forced by his observation that such a trend is more
frequent in Ultra-Bar than in Bar.1 From another perspec-
tive, during the de novo duplication-to-triplication pro-
cess, a chromosome with reversion to normal copy status
or deletion can be produced concurrently with the triplica-
tion chromosome—a normal dosage and absence of a
phenotype would not be readily ascertained in a human
population. So far, one case with somatic CMT1A duplica-
tion reversion has been reported.28 Given the above
evidence, duplications could introduce instability into
meiosis. Duplication could give rise to triplications, allelic
recombinations, reversions, deletions, or a combination
thereof, potentially contributing to clinical variability
within the pedigree affected by duplication. Furthermore,
increased genomic instability might result in susceptibility
to postzygotic mitotic events producing mosaic states29
that could influence disease severity and potentially
account for clinical variability within some families in
which CMT neuropathy segregates.
Theoretically, there are more ways for a chromosome to
acquire a gain in copy number through intrachromosomal
NAHR after a duplication has been introduced into a chro-
mosome (Figure 4). This is partly because the newly, 2014
introduced duplication creates substrate choices that were
not previously available for intrachromosomal NAHR and
thus leads to triplication. For example, at the CMT1A-asso-
ciated locus, only one set of a 24 kb flanking LCR pair is
available for de novo duplication formation (Figure 4C),
whereas three sets (including two homologous recombina-
tion substrate pairs of the 24 kb LCRs [Figures 4D and 4E]
and one pair of a much larger segment, the 1.4 Mb
CMT1A-associated region [Figure 4F]) are available for the
duplication-to-triplication process. In support of the
contention that a chromosome with a duplication has
increased probability of intrachromosomal NAHR, both
de novo triplications examined in this study occurred by
intrachromosomal NAHR, despite the fact that de novo
CMT1A duplications were previously shown to occur pref-
erentially by interchromosomal NAHR (at least 50-fold
greater than intrachromosomal NAHR).26 Other examples
of duplication creating new substrates for NAHR can be
found in the human trypsinogen locus20 and Parkin-
sonism locus,30 the mouse Wallerian degeneration lo-
cus,31 and the fly Bar locus.1 In support of our hypothesis
that intrachromosomal NAHR is favored for the duplica-
tion-to-triplication process, the Parkinson triplication
identified in a Lister kindred was shown to be a result of in-
trachromosomal rearrangement occurring on the founda-
tion of an existing duplication.30
On the basis of these mechanistic predictions, we pro-
pose that triplications are produced at a rate higher than
that of de novo duplications. Re-examination and esti-
mation of frequencies of de novo duplications and tripli-
cations at the fly Bar locus provided empirical data
supporting this hypothesis.1 Two Ultra-Bar mutants were
identified after facet count in 14,000 Bar flies, whereas no
Bar mutation was discovered after eye-size scrutiny in
46,290 full-eye flies (triplication at 2/14,000 versus duplica-
tion at 0/46,290).32 Thus, triplicationsmight bemore prev-
alent in the clinical population than expected, especially
for a condition such as CMT1A, wherein transmission of
duplication is frequently observed and ascertainment bias
between duplication and triplication is trivial.
To this end, we examined the database of a clinical diag-
nostic laboratory performing CMT1A-duplication testing.
The assay applied multiplex-ligation-dependent probe
amplification (MLPA) to examine copy-number or gene
dosage in the 17p12 interval, where the CMT1A-associated
locus resides. MLPA can distinguish the common CMT1A
duplications generated by NAHR from rare smaller and
larger duplications and can also reveal dosage differences
of one, two, three, or four copies.33 We followed the
MLPA data for six years (2007–2012) and used the fre-
quency of identifying four copies versus three copies (the
latter of which was observed with CMT1A duplication) as
a surrogate measure to estimate the frequency of triplica-
tion. Among a total of 20,661 individuals referred for
MLPA testing, 2,758 were identified to have the common
recurrent CMT1A gain. Re-examination and individual
evaluation of the raw data from these 2,758 positive testsThe Ameconfirmed six cases with four copies of the CMT1A-associ-
ated genomic segment on 17p12 (Table S3). Examination
of demographics and molecular investigation of microsat-
ellite markers revealed that five out of the six samples
correspond to unique individuals andmost likely indepen-
dent families (data not shown). These five samples pre-
dicted by the MLPA assay to carry four copies of the
CMT1A-associated region were unanimously confirmed
by array CGH to have equivalent dosage and breakpoint
boundaries consistent with recurrent triplications (Fig-
ure S1). The recurrent nature (flanked by LCRs) of these
rearrangements suggests that they were produced by
NAHR. Theoretically, a recurrent tandem triplication is
thought to be generated from a recurrent duplication
through one NAHR event. Although it has been shown
in other loci that triplication can emerge directly from a
copy-number-neutral region,15,34 such a phenomenon
was always associated with a genomic architecture of in-
verted LCRs and the insertion of one of the triplicated seg-
ments in an inverted orientation (rather than in tandem),
and these do not apply to the CMT1A-associated region.
Therefore, we assumed that each of the five samples re-
flects a potential duplication-to-triplication event. The
five potential triplication carriers were not reported as
consanguineous; genotyping analysis did not reveal an
absence of heterozygosity within the triplication, suggest-
ing that the probability of a homozygous duplication is
slim. However, because of their anonymous identity, we
could not obtain parental samples to completely rule out
the possibility that homozygous duplication contributed
to these five cases. Overall, our data suggest that the de
novo rate of CMT1A triplication arising from duplication
is at least 1.8 3 103 if calculated on the basis that all
five MLPA-detected cases with segmental tetrasomy repre-
sent triplication. The false-negative rate of the MLPA assay
for detecting tetrasomy is unknown. Because of the limita-
tions mentioned above, we might have overestimated (if
one or more of the five candidates carry homozygous du-
plications rather than a triplication) or underestimated
(false-negative detection of triplication via MLPA) the trip-
lication formation rate. Further investigation is warranted
for a more comprehensive estimation.
We sought to compare the frequency of observing tripli-
cation at the CMT1A-associated locus to the de novo dupli-
cation rate. Previous theoretical estimates from population
prevalence data have suggested a locus-specific mutation
rate between 1.7 3 105 and 2.6 3 105.35 Remarkably,
direct experimental studies using pooled sperm PCR
demonstrated a de novo duplication mutation rate of
1.733 105 (54.883 106).26 The agreement of rates esti-
mated from population frequencies and empirical studies
using direct germ cell measurements is consistent with
the idea of an absence of selection against the CMT1A
duplication and no reduced fecundity. Therefore, the
de novo rate of the duplication-to-triplication process is
approximately 100-fold higher than that of the normal-
to-duplication process, supporting our hypothesis thatrican Journal of Human Genetics 94, 462–469, March 6, 2014 465
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Figure 3. Microsatellite Analysis Results Suggest that De Novo Triplications Arose from Duplications by Different NAHRMechanisms
Schematic representation of the CMT1A-associated region in 17p12. Positions of microsatellite markers used in this study are indicated
in (A). Haplotypes were phased on the basis of microsatellite genotyping results in family 1 (B) and family 2 (C). Black indicates a severe
CMT phenotype, and gray indicates the usual degree of neuropathy associated with a CMT1A-duplication phenotype. The numbers
(legend continued on next page)
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Figure 4. More NAHR Pathway Choices
Are Available for the Duplication-to-Tripli-
cation Process than for the Normal-to-
Duplication Process
For simplicity, only chromosome short
arms are shown. The NAHR products
consist of one chromosome with copy-
number gain and the other chromosome
with the reciprocal loss; only the chromo-
some with gain is shown. Yellow, green,
or blue boxes represent the 1.4 Mb
CMT1A-associated segment. Orange ar-
rows indicate LCRs (the 24 kb segmental
duplications that are known to mediate
the de novo CMT1A duplication). Dashed
lines indicate sites of recombination. Inter-
chromosomal NAHR can produce dupli-
cation (A) and triplication (B) similarly.
When NAHR occurs between sister chro-
matids (intrachromosomal), only one pathway (C) exists for de novo duplication, whereas three pathways (D–F) are available for the
production of triplication. Additional (but not exhaustive) possibilities of triplication formation in which oneNAHR (black dashed lines)
and one gene conversion (red dashed lines) are involved are shown in (G)–(J) and potentially explain the rearrangement outcome
in family 1. A distinctive possibility where a quadruplication is first made by an intrachromosomal NAHR but subsequently reverted
to triplication by a gene conversion is shown in (G).the presence of a duplication in one chromosome facili-
tates NAHR to cause a further copy-number gain.
Recurrent triplications are often misdiagnosed as dupli-
cations because of technical challenges in discovery and
validation. In recent years, it has been demonstrated
apodictically that high-density array CGH can robustly
diagnose triplications and differentiate them from duplica-
tions.13,15,16,36 We suggest that such experience and
knowledge about duplication-to-triplication frequencies
can be applied clinically to NAHR-prone regions of the
human genome, where triplications can result in a clinical
phenotype, but not one too severe to be lethal. Several
candidate loci were reported by Dittwald et al., who found
triplications or homozygous duplications of regions in-
cluding NPHP1 (MIM 607100) in 2q13 (n ¼ 4), BP1 and
BP2 in 15q11.2 (n ¼ 1), CHRNA7 (MIM 118511) in
15q13.3 (n ¼ 2), the DiGeorge region in 22q11.21
(n ¼ 3), and the region associated with Prader-Willi and
Angelman syndromes in 15q11.2q13 (n ¼ 1).37 Such
regions might include genomic-disorder-associated loci
similar to the CMT1A-associated locus, such as tetrasomy
of theDiGeorge region.38 Additionally, increasing numbers
of dosage-sensitive regions have been identified by clinical
microarray screening wherein deletion of the region is
clearly associated with disease but the reciprocal duplica-
tion is still of borderline or unknown clinical significance,
presumably because the duplication causes amilder dosage
deviation fromnormal thandoes thedeletion.According toindicated for the microsatellite alleles reflect their numbers of repeat
lication event are highlighted in red. Their inferred origin in themate
backgrounds to illustrate the inferred rearrangement paths. Of note, i
sion event exchanged a segment within the triplication for the alle
phased haplotypes between individual 3329 and the uncle suggested
to the CMT1A duplication in the meiosis that led to either of these t
crossover occurred in the uncle. It is equally possible that the cross
family 2 in individuals KSLIII1 and KSLIII2. Representative raw d
(B) and (C) are shown in (D). Relative peak heights were used for inf
The Ameour hypothesis, these duplications, which are considered
benign variants contributing to a fraction of polymor-
phisms in the general population, could amplify at an un-
expectedly high rate and eventually lead to multiplication,
resulting in adeleterious phenotype. This prediction resem-
bles the genetic phenomenon of anticipation. For example,
duplication of the human Xp22.31 region is considered to
not be sufficient to result in an abnormal phenotype,
whereas triplication of the same region is suggested to cause
neurodevelopmental problems.16 The proposed trend of
amplification could have an impact on various human
genomic disorders and copy-number evolution in the
human genome.
We have demonstrated that recurrent CMT1A triplica-
tion arose from duplications in two families and that the
frequency of such events was orders of magnitude greater
than that of de novo duplication. The CMT1A triplication
causes a severe clinical phenotype, and its prevalence has
been substantially underestimated in the CMT population.
Therefore, individuals with a family history of CMT1A
duplication should be evaluated and counseled for poten-
tial triplications, especially in a CMT1A-duplication-
affected family with an individual considered a ‘‘clinical
outlier’’ or presenting with a phenotypic extreme. Molecu-
larly, we have shown that triplications can be produced
through a variety of NAHR mechanisms. We also provide
evidence suggesting that duplications might be unstable
and undergo allelic recombination when transmitted.s. In the index individual, new alleles reflecting the de novo trip-
rnal chromosome is also colored in red. Alleles are in different color
n the maternal meiosis that led to individual 3328, a gene-conver-
le from the other homologous chromosome. Comparison of the
that an allelic crossover occurred in the chromosomal region distal
wo individuals. One possibility, illustrated in the figure, is that the
over was in individual 3329. A similar condition was observed in
ata of the microsatellite analysis resulting in interpretations in
erring the copy number of each allele.
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Our study further illustrates the concept of clan genomics,
wherein new mutations within a family or clan contribute
to clinically relevant phenotypes against which evolu-
tionary forces have not yet had the time to select.39Supplemental Data
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